Project Grant R01CA318724
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $651K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
- The National Cancer Institute awarded the Regents of the University of Minnesota $101,696 on December 10, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research enhancing TCR-engineered T cell therapy with cytokine fusion proteins for pancreatic cancer treatment. The project, performed in Minneapolis, Minnesota, will define how IL-15 cytokine fusion protein expression augments TCR-T cell function through autocrine and paracrine mechanisms, comparing membrane-bound and...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Rochester $624,494 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate combined stereotactic body radiotherapy and interleukin-12 messenger RNA nanotechnology as a treatment strategy for pancreatic ductal adenocarcinoma. The research targets T cell dynamics in the pancreatic cancer tumor microenvironment by combining localized stereotactic body...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded the University of Mississippi Medical Center $156,000 on June 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize gamma-delta T cell receptor-mediated signaling for improved cancer immunotherapy. The project focuses on investigating how gamma-delta T cells can be engineered to enhance cancer immunotherapy effectiveness. Gamma-delta T cells...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- The National Cancer Institute awarded the Regents of the University of Minnesota $573,262 on April 17, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop autologous humanized leukemia models for immunotherapy testing. The recipient will generate patient-derived xenograft models using paired leukemia and immune cells from the same pre-B acute lymphoblastic leukemia patient, addressing a gap in preclinical testing where current models either lack functional immune systems...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $669,278 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop microbial-based cancer therapeutics engineered to deliver localized immune activation while minimizing systemic toxicity. The research focuses on nonpathogenic, tumor-tropic E. coli engineered to display membrane-anchored cytokines, specifically decoy-resistant...
- The National Cancer Institute awarded Regents of the University of Michigan $660,808 on April 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate tissue-resident memory T cell responses in melanoma patients and their durability following immunotherapy treatment. The work will examine how tissue-resident memory T cells with high interferon gamma expression (TRM-IFNG), established at the time of primary melanoma diagnosis, are recalled and expanded to mediate...
- The National Cancer Institute awarded Dana-Farber Cancer Institute $643,414 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop an interleukin-21 mimic compound, designated 21H10, that enhances anti-tumor immunity in pancreatic ductal adenocarcinoma. The research centers on combining 21H10 with KRAS inhibitors to convert transient therapeutic responses into durable remissions in pancreatic cancer. The compound was developed using AI-assisted computational...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $395,973 to the Regents of the University of Minnesota on July 21, 2026, under the Cancer Biology Research program (CFDA 93.396, assistance type: Project Grant). The award funds research into epitranscriptomic regulation of PAX3-FOXO1 and PAX7-FOXO1 fusion genes in alveolar rhabdomyosarcoma, a pediatric soft tissue sarcoma resistant to current therapies. The investigator's...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...